Innovative Pharmaceutical Biotech (HKSE:00399) Net Income (Continuing Operations) : HK$56.18 Mil (TTM As of Sep. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Innovative Pharmaceutical Biotech's Net Income (Continuing Operations) for the six months ended in Sep. 2023 was HK$192.58 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 was HK$56.18 Mil.

Innovative Pharmaceutical Biotech Net Income (Continuing Operations) Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech Net Income (Continuing Operations) Chart

Innovative Pharmaceutical Biotech Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Net Income (Continuing Operations)

Get a 7-Day Free Trial

-260.91

-222.46

-212.16

36.43

-254.67

Innovative Pharmaceutical Biotech Semi-Annual Data
	Dec13	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Net Income (Continuing Operations)	Get a 7-Day Free Trial															121.11	-84.68	-118.27	-136.40	192.58

Innovative Pharmaceutical Biotech Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$56.18 Mil.

Innovative Pharmaceutical Biotech (HKSE:00399) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Innovative Pharmaceutical Biotech Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech (HKSE:00399) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Net Income (Continuing Operations)

Comparable Companies

Traded in Other Exchanges

N/A

Address

168-200 Connaught Road Central, Unit No. 2111, 21st Floor, Sheung Wan, West Tower Shun Tak Centre, Hong Kong, HKG

Website

http://www.ipb.asia

Innovative Pharmaceutical Biotech Ltd is focused on developing an insulin product that could be administered orally. It has two primary segments of business: the research and development of pharmaceutical products and the trading of beauty products. It generates maximum revenue from trading in the beauty products segment.

Innovative Pharmaceutical Biotech (HKSE:00399) Headlines

No Headlines